Fig. 5.
Protective efficacies of HSV-2 gB and gD antigens in mouse and male guinea pig HSV-2 models. (A) Six- to 8-week-old female BALB/c mice were vaccinated with either 20 μg of gD/CPG/alum, 20 μg of gD/MPL/alum, or a combination of gB-gD/CPG/alum (10 μg of each protein) on days 0 and 28. On day 62, the mice were infected via the intravaginal route with 106 PFU of HSV-2 333. Following infection, the mice were scored daily for 14 days. (B) Male Hartley guinea pigs were immunized by intramuscular injection on days 0 and 28 with 10 μg gB and 10 μg gD in combination with CPG/alum or 20 μg gD in combination with MPL/alum. Following infection, the guinea pigs were scored daily for clinical signs of infection. The error bars indicate standard deviations.